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Abstract
Objective The goal of this study was to evaluate the effectiveness of maropitant (Cerenia®) in preventing
vomiting after premedication with hydromorphone.
Study design Randomized, blinded, prospective clinical study.
Animals Eighteen dogs ASA I/II admitted for elective orthopedic surgical procedures. The dogs were a mixed
population of males and females, purebreds and mixed breeds, 1.0–10.2 years of age, weighing 3–49.5 kg.
Methods Dogs were admitted to the study if they were greater than 1 year of age, healthy and scheduled to
undergo elective orthopedic surgery. Dogs were randomly selected to receive one of two treatments
administered by subcutaneous injection. Group M received 1.0 mg kg−1 of maropitant, Group S received 0.1
mL kg−1 of saline 1 hour prior to anesthesia premedication. Dogs were premedicated with 0.1 mg kg−1 of
hydromorphone intramuscularly. A blinded observer documented the presence of vomiting, retching and/or
signs of nausea for 30 minutes after premedication.
Results All dogs in S vomited (6/9), retched (1/9) or displayed signs of nausea (2/9). None (0/9) of the
dogs in M vomited, retched or displayed signs of nausea. Dogs in M had significantly fewer incidences of
vomiting (p=0.0090), vomiting and retching (p=0.0023) and vomiting, retching and nausea (p<0.0001)
when compared to S.
Conclusion and clinical relevance Maropitant prevents vomiting, retching and nausea associated with
intramuscular hydromorphone administration in dogs.
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Abstract
Objective The goal of this study was to evaluate the
effectiveness of maropitant (Cerenia) in preventing
vomiting after pre-medication with hydromorphone.
Study design Randomized, blinded, prospective clin-
ical study.
Animals Eighteen dogs ASA I/II admitted for elective
orthopedic surgical procedures. Thedogswereamixed
population ofmales and females, purebreds andmixed
breeds, 1.0–10.2 years of age, weighing 3–49.5 kg.
Methods Dogs were admitted to the study if they
were greater than 1 year of age, healthy and
scheduled to undergo elective orthopedic surgery.
Dogs were randomly selected to receive one of two
treatments administered by subcutaneous injection.
Group M received 1.0 mg kg)1 of maropitant,
Group S received 0.1 mL kg)1 of saline 1 hour
prior to anesthesia premedication. Dogs were pre-
medicated with 0.1 mg kg)1 of hydromorphone
intramuscularly. A blinded observer documented
the presence of vomiting, retching and/or signs of
nausea for 30 minutes after premedication.
Results All dogs in S vomited (6/9), retched (1/9) or
displayed signs of nausea (2/9). None (0/9) of the
dogs in M vomited, retched or displayed signs of
nausea. Dogs in M had significantly fewer inci-
dences of vomiting (p = 0.0090), vomiting and
retching (p = 0.0023) and vomiting, retching and
nausea (p < 0.0001) when compared to S.
Conclusion and clinical relevance Maropitant pre-
vents vomiting, retching and nausea associated
with intramuscular hydromorphone administration
in dogs.
Keywords dogs, hydromorphone, maropitant, vomi-
ting.
Introduction
Opioids are commonly used for chemical restraint
and as preanesthetic medications in veterinary
medicine. Full mu-agonists offer dose dependent
sedation and analgesia and are used to treat moder-
ate to severe pain. Theymay also be used as induction
agents and as intra- and post-operative analgesics in
veterinary patients. Adverse side effects may include
respiratory depression, bradycardia, behavioral
changes including sedation, dysphoria or excite-
ment, urine retention and decreased urine produc-
tion and gastrointestinal effects including salivation,
nausea, vomiting and defecation (Wilson 1992;
Branson & Gross 2001; Lamont & Mathews 2007).
Hydromorphone is approximately five to seven
times more potent than morphine, exhibits similar
efficacy, and at equianalgesic doses, produces a
similar adverse effect profile as morphine (Mahler &
Forrest 1975; Coda et al.1997). However, neither
hydromorphone nor oxymorphone were found to
increase plasma histamine concentrations after
intra-venous administration (Smith et al. 2001) as
is seen with morphine (Doenicke et al. 1995).
Oxymorphone also causes less vomiting than either
morphine or hydromorphone in dogs (Valverde
V A A 7 8 8 B Dispatch: 26.9.12 Journal: VAA CE: Sindhuja R.Journal Name Manuscript No. Author Received: No. of pages: 7 PE: Priyadharshini
1





















































et al. 2004) however, it is significantly more
expensive (Pettifer & Dyson 2000). The ability to
give hydromorphone intravenously (IV), without
the risk of histamine release, and the decreased cost,
contribute to its widespread use as an analgesic
drug in veterinary medicine.
The incidence of vomiting in dogs given opioids as
anesthetic pre-medications is 50–75% with mor-
phine (Valverde et al. 2004; Wilson et al. 2007),
44–100% with hydromorphone (Valverde et al.
2004; KuKanich et al. 2008) and 33% with
oxymorphone (Valverde et al. 2004). The incidence
of vomiting is affected by the specific drug and its
lipid solubility profile, the dose and route of admin-
istration and concomitant drug administration.
Decreasing incidence of vomiting is observed with
higher opioid doses, higher lipid solubility and prior
administration of acepromazine (Blancquaert et al.
1986; Hersom & Mackenzie 1987; Gross 2001;
Valverde et al. 2004; KuKanich et al. 2008).
Vomiting and regurgitation, especially when asso-
ciated with anesthesia have been documented as risk
factors for development of aspiration pneumonia
(Fransson et al. 2001;Alwood et al. 2006; Tart et al.
2010). Additional risk factors for aspiration include
underlying esophageal, laryngeal and neurological
disease, prolonged anesthesia, cervical disc lesions
and the use of hydromorphone as an intra-operative
analgesic; all of which can be commonly encountered
in clinical anesthesia practice (Fransson et al. 2001;
Alwood et al. 2006; Kogan et al. 2008; Tart et al.
2010). In addition, vomiting may be particularly
undesirable in certain cases such as penetrating eye
wounds, intra-ocular surgery and patients with head
trauma or a brain tumor where increasing intraoc-
ular or intracranial pressure caused by vomitingmay
lead to increased patient morbidity (Cunningham &
Barry 1986; Yusufu 2002; Slettedal & Bragad 2005;
Eberhart et al. 2007).
Maropitant (Cerenia, Pfizer, NY, USA) is a neu-
rokinin-1 receptor (NK1) antagonist that has been
approved to prevent and treat vomiting in dogs. It
has been shown to be highly effective in preventing
vomiting secondary to a broad spectrum of emetic
stimuli including cisplatin, apomorphine, copper
sulfate, motion sickness and a wide range of clinical
causes of vomiting (Benchaoui et al. 2007; De La
Puente-Rendondo et al. 2007a,b; Vail et al. 2007;
Conder et al. 2008; Ramsey et al. 2008). The goal
of this study was to evaluate the effectiveness of




This study was approved by the Iowa State Uni-
versity Institutional Animal Care and Use Commit-
tee. Dogs presented to the Lloyd Veterinary Medical
Center at Iowa State University College of Veteri-
nary Medicine for elective orthopedic surgery were
included in the study. The owners’ gave consent for
each animal to be included in the study. The study
population included 18 dogs, classified as ASA sta-
tus 1 or 2 based on complete physical examination
and normal routine blood chemistry and complete
blood count. There were 13 spayed females, 4 cas-
trated males and one intact male, aged 1–
11.2 years and weighing 3.0–49.5 kg. Ten different
breeds of dog were represented in the study
including two mixed breed dogs, four Labrador
Retrievers, four Golden Retrievers, and single rep-
resentatives of Boxer, Mastiff, Pomeranian, Brussells
Griffon, Newfoundland, Blue Heeler, German Shep-
herd, Miniature Pinscher.
Study protocol
On entry into the study, dogs were randomly
assigned to receive one of two treatments prior to
preanesthetic medication. Group M received 1.0 mg
kg)1 (0.1 mL kg)1) of maropitant and Group S
received saline 0.1 mL kg)1 subcutaneously 1 hour
prior to anesthesia premedication. The dose of saline
was selected to parallel the volume of maropitant
needed to deliver a 1.0 mg kg)1 dose. All subcuta-
neous injections were administered in the loose skin
on the midline between the scapulae to allow
monitoring of subsequent injection reaction at the
site. Dogs were premedicated with 0.1 mg kg)1 of
hydromorphone intra-muscularly in the lumbar
epaxial muscles. A trained observer blinded to
treatment group documented the emetic events and
the presence of signs of nausea for each dog for
30 minutes after premedication. Vomiting was
defined by expulsion of stomach contents from the
mouth. Retching was defined as forceful contraction
of abdominal muscles without expulsion of stomach
contents from the mouth. Signs interpreted as
nausea included salivation, increased frequency of
or exaggerated swallowing motions and licking of
lips. Each discrete emetic event was recorded. All
dogs were evaluated the following day for pain and
swelling at the injection site.
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The primary variable used in the analysis of efficacy
was whether the dog experienced one or more
vomiting episodes. A two-tailed Fisher exact test
was performed between the treatment and control
group. The Fisher exact test was repeated with the
inclusion of retching and nausea in addition to
vomiting. Statistical significance was assessed at
p £ 0.05. A t-test was used to detect incidental dif-
ferences that may have occurred between the
groups for age and weight. A Fisher exact test was
run for the incidence of vomiting in the saline group
between males and females.
Results
There was no significant difference in age or weight
between dogs in Group M and S
Six of nine dogs (6/9, 66%) that received saline
vomited at least once after hydromorphone
(Table 1). Three dogs (3/9, 33%) vomited only once
and three dogs (3/9, 33%) vomited more than once
after hydromorphone. One dog (1/9, 11%) in the
saline group retched but did not vomit. Two dogs
(2/9, 22%) exhibited signs of nausea including
profuse salivation and lip licking but did not vomit
or retch. Therefore, all dogs in the saline group
vomited, retched or displayed signs of nausea. There
was no significant difference in the incidence of
vomiting between males and females in the saline
group.
None (0/9) of the dogs that received maropitant
vomited, retched or displayed signs of nausea. Dogs
receiving maropitant had significantly fewer inci-
dences of vomiting (p = 0.0090), vomiting and
retching (p = 0.0023) and vomiting, retching and
nausea (p < 0.0001) when compared to saline.
In Group M, one dog exhibited pain on injection
of maropitant. On the day following surgery, there
was no evidence of pain or swelling at the injection
site in dogs receiving either saline or maropitant as
evidenced by observation and palpation.
Discussion
Vomiting involves three stages: nausea, retching
and vomiting (Andrews 1992; Twedt 2000). Nau-
sea is a sensation that precedes vomiting and may
or may not lead to vomiting. Signs of nausea in
animals may include depression, salivation, licking
of lips and increased swallowing. Next, there are
retrograde contractions of the proximal small
intestine and pylorus and relaxation of the fundus
(Twedt 2000; Elwood et al. 2010). Retching is the
second phase and consists of forceful contractions of
the expiratory intercostal muscles, diaphragm and
abdominal muscles with elevation of the larynx and
closure of the glottis (Andrews et al. 1990; Elwood
et al. 2010). Decreased tone in the cervical esoph-
agus, pharyngeal and lower esophageal sphincter,
production of negative intra-thoracic and positive
intra-abdominal pressures and contraction of the
pylorus and antrum of the stomach, are associated
with the movement of gastric contents into the
esophagus (Andrews & Hawthorne 1988; Twedt
2000; Elwood et al. 2010). Vomiting occurs when
gastric contents are expelled from the mouth. Res-
piration is inhibited and the nasopharynx and
glottis close as the vomit passes through the pha-
ryngeal cavity to prevent aspiration (Twedt 2000;
Elwood et al. 2010).
Central neurologic control of vomiting involves a
complex set of activities. There are two anatomically
and functionally separate units: the vomiting or
emetic center which consists of the nucleus tractus
solitarius (NTS) and the dorsal motor nucleus of the
vagus which are located in the medulla oblongata
(Elwood et al. 2010) and the chemoreceptor trigger
zone (CTZ) which has been identified as the area
postrema and is located on the dorsal surface of the
medulla oblongata adjacent to the fourth ventricle
(Elwood et al. 2010). The CTZ lies outside the blood
brain barrier (BBB) and is responsive to circulating
emetogens (Elwood et al. 2010). Emetogenic signals
from the CTZ stimulate neurons of the nucleus
tractus solitarius and from there the central pattern
generator (CPG) of the vomiting reflex which
triggers the motor response (Carpenter et al.
1988; Koga & Fukuda 1992). The vomiting center,
Table 1 Age, weight and sex distribution of dogs receiving
maropitant (Group M) and saline (Group S)
Group Age (years)* Weight (kg)*
Sex
Male Female
M 5.98 ± 2.75 31.7 ± 14.0 2 7
S 5.35 ± 2.75 27.0 ± 16.5 3 6
*Values expressed as mean ± SD; p = 0.6317; p = 0.5249
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which lies within the BBB, integrates efferent input
from a number of sources including the cerebral
cortex (psychogenic vomiting), vestibular input
arising from the semi-circular canals (vomiting
associated with motion sickness or vestibular disor-
ders), vagal and sympathetic afferents from the
gastrointestinal system and other abdominal organs
and the CTZ (Carpenter et al. 1983; Tattersall et al.
1996). Convergence of information from the CTZ
and higher centers in the nucleus tractus solitarius
leads to stimulation of the central pattern generator
(CPG) for vomiting, located in the reticular area,
eliciting the motor act of vomiting (Koga & Fukuda
1992; Fukuda et al. 1999).
Substance P, a neuropeptide in the tachykinin
family and a potent agonist at the NK1 receptor, is
found in high concentrations in areas of the brain
stem involved in emesis including the nucleus
tractus solitarius, the area postrema and the dorsal
motor nucleus of the vagus (Ariumi et al. 2000;
Hargreaves 2002) and is considered to be the key
neurotransmitter involved in vomiting (Diemunsch
& Grelot 2000). Injection of substance P into the
brainstem of ferrets rapidly causes vomiting (Gard-
ner et al. 1995). Vomiting induced by emetogens
such as apomorphine, copper sulfate and cisplatin
can be prevented in dogs by inhibiting NK1 recep-
tors for substance P (Watson et al. 1995). Confir-
mation of the role of NK1 receptors in the final
common pathway in vomiting in dogs came by
selective antagonism of NK1 receptors in decere-
brate dogs exposed to abdominal vagal stimulation
(Fukuda et al. 1999). The proposed site of anti-
emetic action of NK1 receptor antagonists is located
in the CPG or in the pathway connecting the
nucleus tractus solitarius to the CPG (Fukuda et al.
1999; Andrews et al. 2001). NK1 receptor antag-
onists, by acting at the center coordinating the
vomiting response to various central (neural) and
peripheral (humeral) stimuli, can provide broad-
spectrum inhibition of vomiting (Gardner et al.
1996; Fukuda et al. 1999).
Maropitant, a selective NK1 receptor antagonist
has been shown to be effective for prevention of
vomiting caused by stimulation of both central and
peripheral pathways (De La Puente-Rendondo et al.
2007c, Sedlacek et al. 2008). Maropitant has been
shown to significantly reduce vomiting relative to a
saline negative control for both apomorphine (cen-
trally acting emetogen) and syrup of ipecac (periph-
erally acting emetogen). When compared to
metoclopramide, chlorpromazine and ondansetron,
it was the only antiemetic effective against both
centrally (apomorphine) and peripherally (syrup of
ipecac) acting emetogens (Sedlacek et al. 2008).
Hydromorphone has physicochemical properties
very similar to those of morphine (Pettifer & Dyson
2000; Sarhill et al. 2001). Morphine can have both
emetic and anti-emetic effects. The emetic effects are
the result of stimulation of delta receptors outside the
blood/brain barrier (CTZ) whereas the anti-emetic
effects can be attributed to mu-and/or kappa-
mediated mechanisms on the vomiting/emetic cen-
ter (Blancquaert et al. 1986; Hersom & Mackenzie
1987). At low doses (0.3 mg kg)1 IV), morphine
caused vomiting in 6/6 dogs whereas doses of 1 and
2 mg kg)1 resulted in 3/5 and 0/28 incidence of
vomiting respectively (Blancquaert et al. 1986).
The higher doses of morphine also prevented
vomiting induced by apomorphine; 3/5 and 0/23
for doses of 1 and 2 mg kg)1 respectively. It is
postulated that the lower dose of morphine reaches
the CTZ but not the vomiting center, therefore
resulting in emesis, whereas the higher dose can
reach the VC and block the effects on the CTZ
(Blancquaert et al. 1986). Highly lipid soluble
opioids have an anti-emetic effect due to their effect
on the VC. Fentanyl, at doses of 5 and 10 lg kg)1
IV did not cause vomiting in 6/6 and 12/12 dogs
respectively, and 10 lg kg)1 prevented the emetic
effect of apomorphine and copper sulfate in 4/7 and
4/5 dogs respectively (Blancquaert et al. 1986).
Methadone and sufentanil, also highly lipid soluble,
did not cause vomiting in dogs (Blancquaert et al.
1986; Hersom & Mackenzie 1987).
The incidence of vomiting in the saline group was
6/9 (66%). This is slightly higher than previously
reported by Valverde et al. (2004) who found an
incidence of 7/16 (44%) in a group of dogs receiving
hydromorphone (0.1 mg kg)1) intra-muscularly
15 minutes prior to administration of aceproma-
zine. This discrepancy may be due to the relatively
low numbers of dogs in each study or differences in
administration site. All dogs in the present study
were injected in the lumbar epaxial muscles.
Absorption of drugs given in non-postural muscles
is slower than in postural muscles (Self et al. 2009).
Slower absorption may have an effect similar to
lower opioid doses on the CTZ, leading to a more
pronounced emetic effect. The site of intra-muscular
injection was not specified in the Valverde et al.
(2004) study. The incidence of vomiting after intra-
muscular administration is higher than when
hydromorphone is administered intravenously at
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doses of 0.1 mg kg)1 (3/9, 33%) 0.5 mg kg)1 (0/7,
0%) but lower than when administration is by
subcutaneous injection at doses of 0.1 mg kg)1 (6/
8, 75%) and 0.5 mg kg)1 (8/8, 100%) (KuKanich
et al. 2008).
When additional prodromal signs of vomiting
such as retching and nausea were included, a 100%
incidence was observed in the saline group. In
Valverde et al.’s (2004) study, inclusion of retching
and salivation increased the incidence of signs of
vomiting to 28/40 (70%) dogs. However, it was not
indicated whether these dogs received oxymor-
phone, morphine or hydromorphone. However, it
is clear that the incidence of prodromal signs is
higher than overt vomiting.
Acepromazine, when administered at a dose of
0.05 mg kg)1 IM 15 minutes prior to hydromor-
phone, decreased the incidence of vomiting from 7/
16 (44%) to 5/21 (24%), which is thought to be due
to blockade of dopamine receptors in the chemore-
ceptor trigger zone (Valverde et al. 2004). Marop-
itant decreased the incidence of vomiting after
hydromorphone to 0/9, making it a more effective,
reliable anti-emetic.
In human anesthetic patients, satisfaction with
their anesthesia experience is closely tied to the
ability to avoid peri-operative nausea and vomiting.
This issue ranks ahead of pain, death and myocar-
dial infarction as a patient concern. In a recent
interview study of 12,276 patients, 3652 (30%)
reported at least one perioperative complaint, of
these 1705 (46%) were related to perioperative
nausea and vomiting (Lehmann et al. 2010).
Avoiding the discomfort associated with peri-oper-
ative nausea and vomiting may also be a consider-
ation for veterinary patients.
Maropitant was completely effective in preventing
vomiting, retching and nausea associated with
administration of the opioid analgesic hydromor-
phone in this study. The standard dosage recom-
mendations for treatment or prevention of vomiting
are 1.0 mg kg)1 by SC injection or 2.0 mg kg)1 as
oral tablets (De La Puente-Rendondo et al. 2007b).
The pharmacokinetic data demonstrate that in
dogs, these two maropitant doses provide similar
peak plasma concentrations (92 ng mL)1 for
1 mg kg)1 SC, 81 ng mL)1 for 2 mg kg)1 PO) (De
La Puente-Rendondo et al. 2007b). However, the
time taken to achieve maximum plasma concentra-
tion is shorter following SC administration
(0.75 hours for 1 mg kg)1 SC and 1.9 hours for
2 mg kg)1 PO), thus making it the preferred route
of administration in a clinic setting (De La Puente-
Rendondo et al. 2007b). Oral dosing of 2 mg kg)1at
least 2 hours prior to administration of hydromor-
phone may provide a more appropriate route for
owners administering the product at home for the
prevention of emesis prior to a planned elective
surgery where use of hydromorphone or other
opioid drugs that are known to elicit vomiting will
be administered.
The randomized clinical study reported here
demonstrated that maropitant was effective in the
prevention of vomiting after administration of
hydromorphone 0.1 mg kg)1 intra-muscularly
when given 1 hour prior to anesthetic premedica-
tion. Avoidance of peri-operative nausea and vom-
iting may decrease patient discomfort, risk of peri-
operative aspiration pneumonia and morbidity
associated with increased intra-ocular or intra-
cranial pressures.
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